Söndag 23 Februari | 23:04:19 Europe / Stockholm

Prenumeration

2025-02-14 09:56:00

Redeye provides an update on Acarix following its year-end report, which showed softer-than-expected revenues but solid cost control. While the company continues to report supportive news flow and progress in the US, the revenue ramp-up remains slower than anticipated. As a result, we are adjusting our estimates accordingly.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/